PMS-OLMESARTAN-HCTZ TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

可用日期:

PHARMASCIENCE INC

ATC代码:

C09DA08

INN（国际名称）:

OLMESARTAN MEDOXOMIL AND DIURETICS

剂量:

25MG; 40MG

药物剂型:

TABLET

组成:

HYDROCHLOROTHIAZIDE 25MG; OLMESARTAN MEDOXOMIL 40MG

给药途径:

ORAL

每包单位数:

30/100/1000

处方类型:

Prescription

治疗领域:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

產品總結:

Active ingredient group (AIG) number: 0252502003; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2019-02-07

产品特点

PRODUCT MONOGRAPH
Pr
PMS-OLMESARTAN-HCTZ
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg
Angiotensin II AT
1
Receptor Blocker - Diuretic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Quebec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
June 28, 2017
Submission Control No.: 205707, 200930
_ _
_pms-OLMESARTAN-HCTZ Product Monograph _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
.....................................................................